

# US Family Health Plan Prior Authorization Request Form for zanubrutinib (**Brukina**)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:

**Attn: Pharmacy, 77 Warren St, Brighton, MA 02135**

QUESTIONS? **Call 1-877-880-7007**

**Step 1** Please complete patient and physician information (please print):

Patient Name: _____	Physician Name: _____
Address: _____	Address: _____
Sponsor ID #: _____	Phone #: _____
Date of Birth: _____	Secure Fax #: _____

**Step 2** Please complete the clinical assessment:

1. Is the patient greater than or equal to 18 years of age?	<input type="checkbox"/> Yes Proceed to question 2	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
2. Is the requested medication prescribed by or in consultation with a hematologist/oncologist?	<input type="checkbox"/> Yes Proceed to question 3	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
3. For which indication is the requested medication being prescribed?	<input type="checkbox"/> Pathologically confirmed relapsed or refractory mantle cell lymphoma (MCL) – Proceed to question 6 <input type="checkbox"/> Waldenstrom's macroglobulinemia (WM), a rare non-Hodgkin lymphoma – Proceed to question 6 <input type="checkbox"/> Relapsed or refractory marginal zone lymphoma (MZL) who have received at least 1 anti-CD20-based regimen – Proceed to question 6 <input type="checkbox"/> Other – Proceed to question 4	
4. Please provide the indication or diagnosis.	<hr style="width: 80%; margin: 0 auto;"/>  Proceed to question 5	
5. Is the diagnosis cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No <b>STOP</b> Coverage not approved

USFHP Prior Authorization Request Form for  
zanubrutinib (**Brukinsa**)

<p>6. Will the patient be monitored for bleeding, infection (including opportunistic infection), cardiac arrhythmias, secondary primary malignancies, and cytopenias?</p>	<p align="center"><input type="checkbox"/> Yes Proceed to question 7</p>	<p align="center"><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p>7. Will the patient use sun protection in sun-exposed areas?</p>	<p align="center"><input type="checkbox"/> Yes Proceed to question 8</p>	<p align="center"><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p>8. What is the age/gender of the patient?</p>	<p><input type="checkbox"/> Male - Sign and date below  <input type="checkbox"/> Female of childbearing age – Proceed to question 9  <input type="checkbox"/> Female not of childbearing age - Sign and date below</p>	
<p>9. Does the patient agree to use effective contraception during treatment and for at least 1 week after the cessation of treatment?</p>	<p align="center"><input type="checkbox"/> Yes Proceed to question 10</p>	<p align="center"><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p>10. Has it been confirmed that the patient is not pregnant by (-) negative HCG?</p>	<p align="center"><input type="checkbox"/> Yes Proceed to question 11</p>	<p align="center"><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>
<p>11. Has it been confirmed that the patient will avoid breastfeeding during treatment and for at least 2 weeks after the cessation of treatment?</p>	<p align="center"><input type="checkbox"/> Yes Sign and date below</p>	<p align="center"><input type="checkbox"/> No <b>STOP</b> Coverage not approved</p>

**Step 3** I certify the above is true to the best of my knowledge. Please sign and date:

**3**

\_\_\_\_\_ Prescriber Signature

\_\_\_\_\_ Date